A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)

Abstract Aims The ICMR INDIAB-17 study revealed a diabetes prevalence of 11.4% in India, emphasizing the need for effective treatment for glycemic control. A Phase IV study was conducted to evaluate the safety and efficacy of a Fixed Dose Combination (FDC) of Remogliflozin, Metformin and Vildaglipti...

Full description

Saved in:
Bibliographic Details
Main Authors: Prabhat K Agarwal, Divendu Bhushan, Amit Bhate, Sunil Naik, Shailesh Adwani, J S Kushwaha, Sumit Bhushan, Abhishek Mane, Rujuta Gadkari, Sanjay Choudhari, Saiprasad Patil, Hanmant Barkate
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Clinical Diabetes and Endocrinology
Subjects:
Fixed dose combination
Remogliflozin
Vildagliptin
Metformin
Type 2 diabetes
Indian study
Online Access:https://doi.org/10.1186/s40842-024-00210-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40842-024-00210-8

Similar Items